Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

*By submitting your name & email you agree to receive for FREE our scholarships & offers Newsletters. You agree also with the storage and handling of your data by this website and 3rd party email services.
You may unsubscribe if you wish. And you can delete your email and name at any time by emailing us to the email on the bottom of this page.

Follow us on
 
  • Cardioxyl Pharmaceuticals Secures $14.5 Million in Venture Capital Financing

    December 11th, 2006 No comments

    New Enterprise Associates (NEA) has recently announced that it has invested in Cardioxyl Pharmaceuticals. NEA co-led the $14.5 million Series A investment with The Aurora Funds, the proceeds of which will be used to advance the Company’s initial program in acute congestive heart failure. Joining the Cardioxyl board from NEA are James Barrett, PhD, and Robert Garland, MD.

    “Despite the substantial progress made in the treatment of congestive heart failure in recent decades, there remain significant unmet clinical needs,” said NEA’s Dr. Garland. “We’re very impressed with the work that has been done by Cardioxyl’s founders and anticipate that the efforts of these established researchers and executives will, one day, benefit many patients.”

    Cardioxyl’s mission is the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl’s initial program is based on a novel technology developed at Johns Hopkins University by its scientific co-founders David Kass, MD, John P. Toscano, PhD, Nazareno Paolocci, MD, PhD, and their scientific collaborators.

    “NEA’s investment in Cardioxyl is truly a partnership in helping to save lives,” said Peter D. Suzdak, PhD President and CEO of Cardioxyl Pharmaceuticals. “We appreciate that they, together with The Aurora Funds, have a clear grasp of the depth of expertise possessed by our scientists in this field. Few VC firms can rival their knowledge in this sector. We look forward to working closely with NEA to advance new treatments from the laboratory into the clinic.”

    Founded in 2005 and headquartered in Towson, Maryland, Cardioxyl Pharmaceuticals’ mission is the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Their initial program is a novel medication for the treatment of acute congestive heart failure. The treatment is based on extensive scientific work from the laboratories of research leaders at Johns Hopkins University and Medical School and their scientific collaborators.

    For more information, please visit: www.cardioxyl.com

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 266,931 bad guys.

 

Latest Headlines:

Friday August 31, 2012
Zscaler Secures $38 Million Investment Round


Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.


Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects


Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding


Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies


Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains


Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster


Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility


 

By using this website you agree with our cookie policy